Physician profile
Fernando F Corrales-Medina
NPI 1376701524
$335,472.68
in general payments reported to CMS, 2019-2025
20 companies · $100K in 2025
The $100K reported for 2025 was more than what 98% of Pediatric Hematology-Oncology providers received nationally (typical 2025 total: $207).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $10K · 2021: $16K · 2022: $26K · 2023: $37K · 2024: $113K · 2025: $100K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $103K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $75K · Travel and Lodging: $34K · Grant: $20K · Honoraria: $13K · Food and Beverage: $5,729.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $102,929.96 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,741.02 |
| Travel and Lodging | $33,938.11 |
| Grant | $19,800.00 |
| Honoraria | $12,500.00 |
| Food and Beverage | $5,729.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $97,259.21 | 2019-2025 | Novoseven, Rebinyn, Alhemo |
| Octapharma USA, INC. | $59,631.62 | 2019-2025 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human), Nuwiq |
| Genzyme Corporation | $59,395.25 | 2021-2025 | |
| Genentech USA, INC. | $31,737.61 | 2019-2025 | Hemlibra |
| Bayer Healthcare Pharmaceuticals INC. | $25,135.41 | 2022-2025 | |
| Shire North American Group INC | $19,491.94 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14,241.19 | 2020-2025 | Advate, Adynovate |
| Biomarin Pharmaceutical INC. | $11,843.32 | 2022-2024 | Roctavian |
| Csl Behring | $8,551.11 | 2020-2024 | Hemgenix, Idelvion |
| Pfizer INC. | $4,400.00 | 2025 | |
| Bioverativ Therapeutics INC. | $3,413.00 | 2020 | |
| Genentech, INC. | $149.73 | 2023-2025 | Hemlibra |
| Hema Biologics, LLC | $139.50 | 2025 | |
| Novartis Pharmaceuticals Corporation | $32.57 | 2019 | |
| Amgen INC. | $31.97 | 2020 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Duchesnay USA Incorporated | $19.25 | 2022 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fernando Corrales-Medina listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.